Literature DB >> 28501635

Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.

Jie Zhang1, Angela G Fleischman2, Dominik Wodarz3, Natalia L Komarova4.   

Abstract

Myeloproliferative neoplasm (MPN) is a hematologic malignancy characterized by the clonal outgrowth of hematopoietic cells with a somatically acquired mutation most commonly in JAK2 (JAK2V617F). This mutation endows upon myeloid progenitors cytokine independent growth and consequently leads to excessive production of myeloid lineage cells. It has been previously suggested that inflammation may play a role in the clonal evolution of JAK2V617F mutants. In particular, it is possible that one or more cellular kinetic parameters of hematopoietic stem cells (HSCs) are affected by inflammation, such as division or death rates of cells, and the probability of HSC differentiation. This suggests a mechanism that can steer the outcome of the cellular competition in favor of the mutants, initiating the disease. In this paper we create a number of mathematical evolutionary models, from very abstract to more concrete, that describe cellular competition in the context of inflammation. It is possible to build a model axiomatically, where only very general assumptions are imposed on the modeling components and no arbitrary (and generally unknown) functional forms are used, and still generate a set of testable predictions. In particular, we show that, if HSC death is negligible, the evolutionary advantage of mutant cells can only be conferred by an increase in differentiation probability of HSCs in the presence of inflammation, and if death plays a significant role in the dynamics, an additional mechanism may be an increase of HSC's division-to-death ratio in the presence of inflammation. Further, we show that in the presence of inflammation, the wild type cell population is predicted to shrink under inflammation (even in the absence of mutants). Finally, it turns out that if only the differentiation probability is affected by the inflammation, then the resulting steady state population of wild type cells will contain a relatively smaller percentage of HSCs under inflammation. If the division-to-death rate is also affected, then the percentage of HSCs under inflammation can either decrease or increase, depending on other parameters.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Axiomatic modeling; Evolutionary dynamics; Hematopoietic disease; ODE modeling

Mesh:

Substances:

Year:  2017        PMID: 28501635      PMCID: PMC5689470          DOI: 10.1016/j.jtbi.2017.05.012

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  34 in total

1.  CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.

Authors:  Jeffrey W Tyner; Thomas G Bumm; Jutta Deininger; Lisa Wood; Karl J Aichberger; Marc M Loriaux; Brian J Druker; Christopher J Burns; Emmanuelle Fantino; Michael W Deininger
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Authors:  Angela G Fleischman; Karl J Aichberger; Samuel B Luty; Thomas G Bumm; Curtis L Petersen; Shirin Doratotaj; Kavin B Vasudevan; Dorian H LaTocha; Fei Yang; Richard D Press; Marc M Loriaux; Heike L Pahl; Richard T Silver; Anupriya Agarwal; Thomas O'Hare; Brian J Druker; Grover C Bagby; Michael W Deininger
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 5.  Somatic mutations and the hierarchy of hematopoiesis.

Authors:  Arne Traulsen; Jorge M Pacheco; Lucio Luzzatto; David Dingli
Journal:  Bioessays       Date:  2010-08-27       Impact factor: 4.345

Review 6.  A systems-theoretical framework for health and disease: inflammation and preconditioning from an abstract modeling point of view.

Authors:  Eberhard O Voit
Journal:  Math Biosci       Date:  2008-09-27       Impact factor: 2.144

7.  Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a.

Authors:  Stefanie Slezak; Ping Jin; Lorraine Caruccio; Jiaqiang Ren; Michael Bennett; Nausheen Zia; Sharon Adams; Ena Wang; Joao Ascensao; Geraldine Schechter; David Stroncek
Journal:  J Transl Med       Date:  2009-06-04       Impact factor: 5.531

Review 8.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

Authors:  Peter M Rothwell; Jacqueline F Price; F Gerald R Fowkes; Alberto Zanchetti; Maria Carla Roncaglioni; Gianni Tognoni; Robert Lee; Jill F F Belch; Michelle Wilson; Ziyah Mehta; Tom W Meade
Journal:  Lancet       Date:  2012-03-21       Impact factor: 79.321

9.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.

Authors:  Peter M Rothwell; Michelle Wilson; Jacqueline F Price; Jill F F Belch; Tom W Meade; Ziyah Mehta
Journal:  Lancet       Date:  2012-03-21       Impact factor: 79.321

Review 10.  The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.

Authors:  Jonas S Jutzi; Heike L Pahl
Journal:  Mediators Inflamm       Date:  2015-10-12       Impact factor: 4.711

View more
  2 in total

1.  Targeted sequencing of candidate gene regions for myelofibrosis in dogs.

Authors:  Amelia G Campbell; Davis M Seelig; Joan D Beckman; Katie M Minor; Daniel A Heinrich; Steven G Friedenberg; Jaime F Modiano; Eva Furrow
Journal:  J Vet Intern Med       Date:  2022-07-11       Impact factor: 3.175

Review 2.  The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies.

Authors:  Brianna M Craver; Kenza El Alaoui; Robyn M Scherber; Angela G Fleischman
Journal:  Cancers (Basel)       Date:  2018-04-03       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.